Xiaoxi Yao

Xiaoxi Yao

Auto-generated profile, based on publicly available information

Xiaoxi Yao

Department of Neurology, The First People’s Hospital of Chenzhou, Hunan, China (X.Y.).

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
XYXiaoxi Yao
Xiaoxi Yao
RYRui Yao
Rui Yao
FHFengzhen Huang
Fengzhen Huang
JYJiping Yi
Jiping Yi

1 March 2019 in Neuroscience Letters
Verified
Journal Article
Closed access
XYXiaoxi Yao
Xiaoxi Yao
RYRui Yao
Rui Yao
JYJiping Yi
Jiping Yi
FHFengzhen Huang
Fengzhen Huang

18 November 2025 in Circulation
Verified
Journal Article
Closed access
FGFeng Gao
Feng Gao
XTXu Tong
Xu Tong
MWMing Wei
Ming Wei
XYXiaoxi Yao
Xiaoxi Yao
LLLei Li
Lei Li
OGon behalf of the ANGEL-REBOOT Study Group
on behalf of the ANGEL-REBOOT Study Group
BACKGROUND: The long-term benefits of bailout intracranial angioplasty or stenting (BAOS) after thrombectomy in patients with acute large vessel occlusion remain unclear. This study compared BAOS with standard therapy in patients with large vessel occlusion with unsuccessful recanalization (expanded Thrombolysis In Cerebral Infarction score 0–2a) or >70% residual stenosis after thrombectomy. METHODS: ANGEL-REBOOT (Randomized Study of Bailout Intracranial Angioplasty Following Thrombectomy for Acute Large Vessel Occlusion) was a multicenter, open-label, blinded–end point, randomized trial conducted across 36 Chinese hospitals. Patients ≥18 years of age with anterior or posterior circulation large vessel occlusion within 24 hours of stroke onset were enrolled. After identification of thrombectomy failure or high-grade residual stenosis, patients were randomly assigned to the BAOS group (intervention) or the standard therapy group (control), in which thrombectomy was continued or terminated. The use of tirofiban was permitted in both groups during and after the procedure. In the intention-to-treat population, the primary outcome was analyzed using an assumption-free ordinal analysis (Wilcoxon-Mann-Whitney test) to compare the modified Rankin Scale scores (ordinal variable ranging from 0 to 6) between groups at 1-year follow-up, from which the generalized odds ratio was derived. Secondary outcomes included stroke recurrence in the treated artery and all-cause mortality within 1 year, analyzed using Cox proportional hazards models. RESULTS: A total of 348 patients were randomly assigned (176 to the BAOS group and 172 to the standard therapy group) and followed for 90 days, from December 19, 2021, to June 2, 2023. Of these, 326 patients (166 in the BAOS group and 160 in the standard therapy group) completed the 1-year follow-up. Compared with standard therapy, BAOS significantly improved the 1-year modified Rankin Scale score distribution (generalized odds ratio, 1.34 [95% CI, 1.05–1.73]; P =0.02). Fewer stroke recurrences in the treated artery occurred in the BAOS group than in the standard therapy group (7 of 166 [4%] versus 21 of 160 [13%]; hazard ratio, 0.30 [95% CI, 0.13–0.71]; P =0.006). One-year mortality rates were similar between groups (25 of 166 [15%] versus 27 of 160 [17%]; hazard ratio, 0.87 [95% CI, 0.50–1.50]). CONCLUSIONS: Among Chinese patients with large vessel occlusion with unsuccessful recanalization or high-grade residual stenosis after thrombectomy, BAOS was associated with reduced disability and stroke recurrence after 1 year compared with standard therapy. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05122286.

18 October 2021 in Acta Neurologica Belgica
Verified
Journal Article
Open access
PDF file
JHJing Han
Jing Han
GFGanghua Feng
Ganghua Feng
JWJibao Wu
Jibao Wu
YZYi Zhang
Yi Zhang
ZLZhipeng Long
Zhipeng Long
XYXiaoxi Yao
Xiaoxi Yao
Purpose: There is growing evidence that autophagy-related gene 5 (ATG5) is involved in neural development, neuronal differentiation, and neurodegenerative diseases. The purpose of this study was to investigate the association between ATG5 gene single-nucleotide polymorphisms (SNPs) and Parkinson’s disease (PD) in the Han population. Methods: A case–control study was conducted in 120 PD patients and 100 healthy volunteers. MassArray platform was used to analyze polymorphisms in three different regions of ATG5 gene (rs510432, rs573775 and rs17587319). In the included subjects, 50 PD patients and 50 healthy volunteers were selected, and the plasma ATG5 concentration was detected by enzyme-linked immunosorbent assay (ELISA). The allele and genotype frequencies of SNPs were assessed using the SHEsis program. Results: We found a significant correlation between rs17587319 and PD, and the subcomponent showed a high correlation between rs17587319 with cognitive impairment and age at onset in PD patients. At the same time, the total plasma ATG5 level of PD patients and the plasma ATG5 expression level of early-onset Parkinson’s disease (EOPD) patients were significantly higher than the control group, while there was no significant difference of ATG5 expression between late-onset Parkinson’s disease (LOPD) patients and the control group. Conclusion: These findings suggest that genetic variations in the ATG5 gene and low levels of the ATG5 protein are associated with susceptibility to PD and with cognitive impairment in PD patients. ATG5 could be a potential biomarker to assess the severity and prognosis of PD.

15 July 2022
Verified
Journal Article
Closed access
JHJing Han
Jing Han
GFGang-Hua Feng
Gang-Hua Feng
HLHua-Wu Liu
Hua-Wu Liu
JYJi-Ping Yi
Ji-Ping Yi
JWJi-Bao Wu
Ji-Bao Wu
XYXiao-Xi Yao
Xiao-Xi Yao

20 May 2026 in Metabolic Brain Disease
Verified
Journal Article
Closed access
GFGanghua Feng
Ganghua Feng
YHYabin Hu
Yabin Hu
QLQiuli Li
Qiuli Li
JWJibao Wu
Jibao Wu
YLYuanbiao Lei
Yuanbiao Lei
XYXiaoxi Yao
Xiaoxi Yao